帕博利珠单抗相关性重度黏膜炎：两例报告、文献复习及治疗方案算法。
Severe Mucositis Secondary to Pembrolizumab: Reports of Two Cases, Review of the Literature, and an Algorithm for Management.
机构信息
Resident, Department of Oral and Maxillofacial Surgery, Temple University, Former Non-Categorical Intern University of Washington, Seattle, WA.
Acting Assistant Professor, Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA.
出版信息
J Oral Maxillofac Surg. 2021 Jun;79(6):1262-1269. doi: 10.1016/j.joms.2020.11.023. Epub 2020 Nov 30.
The indications for use of programed cell death receptor (PD-1) inhibitors to treat cancer continues to expand rapidly. Treatment with PD-1 inhibitors has been associated with numerous immune-mediated mucocutaneous side effects. Here, we report 2 cases of severe mucositis caused by the PD-1 inhibitor pembrolizumab and review the defining features of similar cases. Recognition of mucocutaneous toxicities of PD-1 inhibitors is increasingly important as their use continues to expand. A stepwise approach to diagnosis and management is also reviewed.
程序性细胞死亡受体（PD-1）抑制剂用于治疗癌症的适应证不断迅速扩大。PD-1 抑制剂的治疗与许多免疫介导的黏膜皮肤副作用相关。在这里，我们报告了 2 例由 PD-1 抑制剂派姆单抗引起的严重黏膜炎病例，并回顾了类似病例的特征。随着 PD-1 抑制剂的使用不断扩大，识别其黏膜皮肤毒性变得越来越重要。还回顾了诊断和管理的逐步方法。
Zotero 插件